Please login to the form below

Not currently logged in
Email:
Password:

Avanir

This page shows the latest Avanir news and features for those working in and with pharma, biotech and healthcare.

Otsuka presses on with Alzheimer’s agitation drug

Otsuka presses on with Alzheimer’s agitation drug

The investigational therapy is a new formulation of the active ingredients in Otsuka/Avanir's already-marketed Nuedexta (deudextromethorphan hydrobromide/quinidine sulphate) product. ... Otsuka and Avanir are also studying AVP-786 in mid-stage trials as

Latest news

  • Avanir’s week goes from bad to worse with Alzheimer’s stumble Avanir’s week goes from bad to worse with Alzheimer’s stumble

    Otsuka’s Avanir unit has been dealt yet another setback after its second phase 3 trial of its new drug for agitation in Alzheimer’s disease missed the mark. ... Otsuka paid $3.5bn to  acquire Avanir in 2014 as part of a strategy to expand its

  • Otsuka’s Alzheimer’s agitation drug hits the mark Otsuka’s Alzheimer’s agitation drug hits the mark

    All three drug classes have side effect issues, including drowsiness. AVP-786 – developed by Otsuka subsidiary Avanir in collaboration with Concert Pharma – offers the promise of a new medicine that could ... bridge the treatment gap” in agitated

  • Otsuka expands CNS presence with Avanir purchase Otsuka expands CNS presence with Avanir purchase

    Deal for US biotech is valued at $3.5bn. Japan-based Otsuka Pharmaceutical has agreed to buy the California biotech Avanir for $3.5bn, expanding its business in diseases of the ... Avanir also has a promising pipeline, including the compound AVP-786,

  • Avanir to co-promote Merck's diabetes drugs in the US Avanir to co-promote Merck's diabetes drugs in the US

    Under the agreement, Avanir will promote these products to healthcare professionals working in long-term care institutional setting, such as care homes. ... Rohan Palekar, chief commercial officer at Avanir, confirmed Merck's ambitions in the area.

  • Genzyme appoints MS and rare diseases business leaders

    He joins Genzyme from Avanir Pharmaceuticals, where he was the chief commercial officer, leading all of the company's commercial activities.

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics